Switch theme
Sign up to access all valuation multiples
Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.
2002
5.6K+
LTM Revenue $5.7B
LTM EBITDA $1.1B
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genscript Biotech has a last 12-month revenue (LTM) of $5.7B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, Genscript Biotech achieved revenue of $75.9M and an EBITDA of -$10.9M.
Genscript Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genscript Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.7B | XXX | $75.9M | XXX | XXX | XXX |
| Gross Profit | $3.0B | XXX | $34.7M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | -$10.9M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | -14% | XXX | XXX | XXX |
| EBIT | $648M | XXX | $2.9M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $14.1B | XXX | $378M | XXX | XXX | XXX |
| Net Margin | 247% | XXX | 498% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genscript Biotech's stock price is HKD 13 (or $2).
Genscript Biotech has current market cap of HKD 27.9B (or $3.6B), and EV of HKD 24.4B (or $3.1B).
See Genscript Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $3.6B | XXX | XXX | XXX | XXX | $0.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genscript Biotech has market cap of $3.6B and EV of $3.1B.
Genscript Biotech's trades at 41.0x EV/Revenue multiple, and -286.5x EV/EBITDA.
Equity research analysts estimate Genscript Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genscript Biotech has a P/E ratio of 2.0x.
See valuation multiples for Genscript Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 41.0x | XXX | XXX | XXX |
| EV/EBITDA | 22.8x | XXX | -286.5x | XXX | XXX | XXX |
| EV/EBIT | 37.6x | XXX | 1073.4x | XXX | XXX | XXX |
| EV/Gross Profit | 8.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 2.0x | XXX | 9.4x | XXX | XXX | XXX |
| EV/FCF | 99.4x | XXX | -337.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenscript Biotech's last 12 month revenue growth is 20%
Genscript Biotech's revenue per employee in the last FY averaged $14K, while opex per employee averaged $6K for the same period.
Genscript Biotech's rule of 40 is -10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genscript Biotech's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genscript Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 225% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Growth | 85% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10% | XXX | 6% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genscript Biotech acquired XXX companies to date.
Last acquisition by Genscript Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Genscript Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genscript Biotech founded? | Genscript Biotech was founded in 2002. |
| Where is Genscript Biotech headquartered? | Genscript Biotech is headquartered in Hong Kong. |
| How many employees does Genscript Biotech have? | As of today, Genscript Biotech has 5.6K+ employees. |
| Is Genscript Biotech publicy listed? | Yes, Genscript Biotech is a public company listed on HKG. |
| What is the stock symbol of Genscript Biotech? | Genscript Biotech trades under 01548 ticker. |
| When did Genscript Biotech go public? | Genscript Biotech went public in 2015. |
| Who are competitors of Genscript Biotech? | Similar companies to Genscript Biotech include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Genscript Biotech? | Genscript Biotech's current market cap is $3.6B |
| What is the current revenue of Genscript Biotech? | Genscript Biotech's last 12 months revenue is $5.7B. |
| What is the current revenue growth of Genscript Biotech? | Genscript Biotech revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Genscript Biotech? | Current revenue multiple of Genscript Biotech is 4.3x. |
| Is Genscript Biotech profitable? | Yes, Genscript Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genscript Biotech? | Genscript Biotech's last 12 months EBITDA is $1.1B. |
| What is Genscript Biotech's EBITDA margin? | Genscript Biotech's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Genscript Biotech? | Current EBITDA multiple of Genscript Biotech is 22.8x. |
| What is the current FCF of Genscript Biotech? | Genscript Biotech's last 12 months FCF is $245M. |
| What is Genscript Biotech's FCF margin? | Genscript Biotech's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Genscript Biotech? | Current FCF multiple of Genscript Biotech is 99.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
